Aflibercept in the treatment of metastatic colorectal cancer.

Abstract

Colorectal cancer is the third most common cancer in the US. In recent decades, an improved understanding of the role of the angiogenesis pathway in colorectal cancer has led to advancements in treatment. Bevacizumab has been shown to improve the progression-free survival and overall survival when combined with cytotoxic chemotherapy in patients with metastatic colorectal cancer, and at present is the only antiangiogenesis agent approved for the treatment of this cancer. Aflibercept is a novel angiogenesis-targeting agent, and has demonstrated efficacy in treating metastatic colorectal cancer in a recent randomized Phase III trial. Here we review the role of angiogenesis in the tumorigenesis of colorectal cancer, strategies for targeting angiogenesis, and the clinical development of aflibercept.

• Authors: Tzu-Fei Wang, Albert Craig Lockhart
• Journal: Clinical Medicine Insights. Oncology (Clin Med Insights Oncol) Vol. 6 Pg. 19-30 ( 2012) ISSN: 1179-5549 [Electronic] United States
• PMID: 22253552 (Publication Type: Journal Article)